Amgen reported a slight year-over-year revenue decline but offset this with improved operating margins and raised full-year EPS guidance, reflecting effective cost management and strategic initiatives like the GSK partnership. The positive outlook and strong management tone are likely to enhance investor confidence in the short term.

[1]